CN117534754A - Cd38调节抗体 - Google Patents
Cd38调节抗体 Download PDFInfo
- Publication number
- CN117534754A CN117534754A CN202311290186.4A CN202311290186A CN117534754A CN 117534754 A CN117534754 A CN 117534754A CN 202311290186 A CN202311290186 A CN 202311290186A CN 117534754 A CN117534754 A CN 117534754A
- Authority
- CN
- China
- Prior art keywords
- antibody
- acd38
- seq
- amino acid
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (34)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517149P | 2017-06-08 | 2017-06-08 | |
| US201762517150P | 2017-06-08 | 2017-06-08 | |
| US62/517,150 | 2017-06-08 | ||
| US62/517,149 | 2017-06-08 | ||
| US201762517165P | 2017-06-09 | 2017-06-09 | |
| US201762517164P | 2017-06-09 | 2017-06-09 | |
| US201762517745P | 2017-06-09 | 2017-06-09 | |
| US201762517734P | 2017-06-09 | 2017-06-09 | |
| US201762517753P | 2017-06-09 | 2017-06-09 | |
| US201762517740P | 2017-06-09 | 2017-06-09 | |
| US62/517,164 | 2017-06-09 | ||
| US62/517,740 | 2017-06-09 | ||
| US62/517,745 | 2017-06-09 | ||
| US62/517,753 | 2017-06-09 | ||
| US62/517,165 | 2017-06-09 | ||
| US62/517,734 | 2017-06-09 | ||
| US201762546330P | 2017-08-16 | 2017-08-16 | |
| US201762546322P | 2017-08-16 | 2017-08-16 | |
| US62/546,330 | 2017-08-16 | ||
| US62/546,322 | 2017-08-16 | ||
| US201762582666P | 2017-11-07 | 2017-11-07 | |
| US201762582676P | 2017-11-07 | 2017-11-07 | |
| US201762582616P | 2017-11-07 | 2017-11-07 | |
| US201762582653P | 2017-11-07 | 2017-11-07 | |
| US201762582681P | 2017-11-07 | 2017-11-07 | |
| US201762582628P | 2017-11-07 | 2017-11-07 | |
| US62/582,653 | 2017-11-07 | ||
| US62/582,628 | 2017-11-07 | ||
| US62/582,681 | 2017-11-07 | ||
| US62/582,676 | 2017-11-07 | ||
| US62/582,616 | 2017-11-07 | ||
| US62/582,666 | 2017-11-07 | ||
| PCT/EP2018/065237 WO2018224682A1 (en) | 2017-06-08 | 2018-06-08 | Cd38 modulating antibody |
| CN201880049280.1A CN111051344B (zh) | 2017-06-08 | 2018-06-08 | Cd38调节抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880049280.1A Division CN111051344B (zh) | 2017-06-08 | 2018-06-08 | Cd38调节抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117534754A true CN117534754A (zh) | 2024-02-09 |
Family
ID=62620845
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311290186.4A Pending CN117534754A (zh) | 2017-06-08 | 2018-06-08 | Cd38调节抗体 |
| CN201880049280.1A Active CN111051344B (zh) | 2017-06-08 | 2018-06-08 | Cd38调节抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880049280.1A Active CN111051344B (zh) | 2017-06-08 | 2018-06-08 | Cd38调节抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11780930B2 (https=) |
| EP (1) | EP3635001A1 (https=) |
| JP (3) | JP7679196B2 (https=) |
| CN (2) | CN117534754A (https=) |
| AU (2) | AU2018280868B2 (https=) |
| CA (1) | CA3066547A1 (https=) |
| WO (1) | WO2018224682A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110144008B (zh) * | 2018-02-12 | 2021-03-19 | 杭州尚健生物技术有限公司 | Cd38蛋白抗体及其应用 |
| US20200345725A1 (en) | 2019-01-11 | 2020-11-05 | Omeros Corporation | Methods and Compositions for Treating Cancer |
| AU2020353660A1 (en) * | 2019-09-26 | 2022-04-14 | Orionis Biosciences, Inc. | PD-L1 targeted chimeric proteins and uses thereof |
| CN114616245B (zh) * | 2019-12-13 | 2024-02-23 | 山东先声生物制药有限公司 | 一种抗cd38的抗体及其用途 |
| US12497463B2 (en) | 2020-06-23 | 2025-12-16 | Jiangsu Kanion Pharmaceutical Co., Ltd. | Anti-CD38 antibody and use thereof |
| CN114075283A (zh) * | 2020-08-12 | 2022-02-22 | 三生国健药业（上海）股份有限公司 | 结合人cd38的抗体、其制备方法和用途 |
| US12181485B2 (en) | 2020-09-10 | 2024-12-31 | CASI Pharmaceuticals, Inc | Methods of blood screening |
| CN116635420A (zh) * | 2020-09-10 | 2023-08-22 | 英创远达制药公司 | 血液筛查方法 |
| CN114437215B (zh) * | 2020-11-05 | 2023-02-07 | 上海麦济生物技术有限公司 | 抗人cd38抗体及其制备方法和用途 |
| CN120456924A (zh) * | 2023-01-05 | 2025-08-08 | 丹娜-法伯癌症研究院 | Kit细胞表面受体的表位工程化 |
| WO2025166138A1 (en) * | 2024-02-02 | 2025-08-07 | Triveni Bio, Inc. | Klk5/7 + tslp targeting antibodies and uses thereof |
| WO2025166146A1 (en) * | 2024-02-02 | 2025-08-07 | Triveni Bio, Inc. | Klk5/7 + ox40 targeting antibodies and uses thereof |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| DK2511297T3 (en) | 2004-02-06 | 2015-06-15 | Morphosys Ag | Human anti-CD38 antibodies and their applications |
| US8263746B2 (en) | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
| EP2567976B1 (en) | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| TW200745162A (en) | 2005-05-24 | 2007-12-16 | Morphosys Ag | Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 |
| EP2860192B1 (en) | 2005-10-12 | 2017-09-27 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 |
| AU2013209322A1 (en) * | 2006-10-19 | 2013-08-15 | Sanofi-Aventis | Novel anti-cd38 antibodies for the treatment of cancer |
| CN101605906A (zh) * | 2006-12-14 | 2009-12-16 | 梅达雷克斯公司 | 结合cd70的人类抗体及其用途 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US8691730B2 (en) | 2007-09-14 | 2014-04-08 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| AU2009301580B2 (en) | 2008-10-06 | 2015-11-26 | The University Of British Columbia | Methods and systems for predicting misfolded protein epitopes |
| SG178925A1 (en) | 2009-09-22 | 2012-04-27 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
| DK2593594T3 (en) | 2010-07-16 | 2017-12-11 | Adimab Llc | ANTIBODY LIBRARIES |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| JP2017506640A (ja) | 2014-02-14 | 2017-03-09 | セントローズ， エルエルシー | 細胞外標的化薬物共役体 |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) * | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| MA40894A (fr) | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| ES2927119T3 (es) | 2015-04-08 | 2022-11-02 | Sorrento Therapeutics Inc | Productos terapéuticos de anticuerpos que se unen a CD38 |
| GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| MX389805B (es) | 2015-05-20 | 2025-03-11 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38. |
| HRP20240338T1 (hr) | 2015-06-24 | 2024-05-24 | Janssen Biotech, Inc. | Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38 |
| CA2997444A1 (en) | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors for reducing cholesterol levels |
| PE20240096A1 (es) | 2015-10-02 | 2024-01-18 | Hoffmann La Roche | Anticuerpos biespecificos especificos para un receptor de tnf coestimulador |
-
2018
- 2018-06-08 WO PCT/EP2018/065237 patent/WO2018224682A1/en not_active Ceased
- 2018-06-08 CA CA3066547A patent/CA3066547A1/en active Pending
- 2018-06-08 CN CN202311290186.4A patent/CN117534754A/zh active Pending
- 2018-06-08 AU AU2018280868A patent/AU2018280868B2/en active Active
- 2018-06-08 EP EP18731392.9A patent/EP3635001A1/en active Pending
- 2018-06-08 JP JP2020518571A patent/JP7679196B2/ja active Active
- 2018-06-08 CN CN201880049280.1A patent/CN111051344B/zh active Active
- 2018-06-08 US US16/620,584 patent/US11780930B2/en active Active
-
2023
- 2023-06-14 JP JP2023097445A patent/JP7596447B2/ja active Active
- 2023-09-01 US US18/460,069 patent/US20240092928A1/en active Pending
-
2024
- 2024-11-11 AU AU2024259884A patent/AU2024259884A1/en active Pending
- 2024-11-27 JP JP2024205869A patent/JP2025028972A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200190209A1 (en) | 2020-06-18 |
| NZ759835A (en) | 2025-09-26 |
| US11780930B2 (en) | 2023-10-10 |
| WO2018224682A1 (en) | 2018-12-13 |
| AU2018280868B2 (en) | 2024-09-26 |
| AU2024259884A1 (en) | 2025-01-02 |
| JP2025028972A (ja) | 2025-03-05 |
| JP2020523038A (ja) | 2020-08-06 |
| CN111051344A (zh) | 2020-04-21 |
| CA3066547A1 (en) | 2018-12-13 |
| US20240092928A1 (en) | 2024-03-21 |
| JP2023116681A (ja) | 2023-08-22 |
| EP3635001A1 (en) | 2020-04-15 |
| CN111051344B (zh) | 2023-10-27 |
| JP7679196B2 (ja) | 2025-05-19 |
| JP7596447B2 (ja) | 2024-12-09 |
| AU2018280868A1 (en) | 2020-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7596447B2 (ja) | Ｃｄ３８調節抗体 | |
| CN110997722B (zh) | Cd38调节抗体 | |
| CN111032086B (zh) | Cd38抗体 | |
| US12304964B2 (en) | CD38 modulating antibody | |
| US11542338B2 (en) | CD38 modulating antibody | |
| KR102770104B1 (ko) | Cd38 조정 항체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |